Lutetium-177 DOTA satoreotide

Drug Profile

Lutetium-177 DOTA satoreotide

Alternative Names: 177Lu-DOTA- JR11; 177LU-OPS 201; 177Lu-satoreotide; OPS201; SOMther®

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OctreoPharm Sciences
  • Developer Ipsen; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Drug conjugates; Peptides; Somatostatins
  • Mechanism of Action Somatostatin receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Neuroendocrine tumours

Most Recent Events

  • 02 Jun 2017 Preliminary efficacy and adverse events data from a phase I trial in Neuroendocrine tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top